Diapin Therapeutics

Novel Therapies for Cardiovascular and Metabolic Diseases

Diapin Therapeutics is active in the health & longevity space based in Seattle, Washington.

Profile

Diapin Therapeutics is a health and lifetech company focused on developing novel therapies for cardiovascular and metabolic diseases. The company’s mission centers on advancing innovative treatments to address critical unmet medical needs in these areas. Its key products include DT678, a best-in-class anti-platelet therapy designed to prevent stroke and heart attacks in cardiovascular disease patients, and DT109, a peptide targeting metabolic conditions such as non-alcoholic fatty liver disease (NAFLD), metabolic-associated steatohepatitis (MASH), and atherosclerosis. Both assets originated from academic research and are progressing through clinical and preclinical development stages. Diapin Therapeutics contributes to medical innovation by translating cutting-edge scientific discoveries into promising therapeutic candidates aimed at improving patient outcomes in complex chronic diseases.

Its activity falls under health & longevity; the profile below is assembled from public directory data.

Its base of operations is Seattle, Washington.

The company is listed at the Plug and Play accelerated startup stage of development.

Website: www.diapin.com